FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3207645374> ?p ?o ?g. }

• W3207645374 endingPage "e251" @default.
• W3207645374 startingPage "e247" @default.
• W3207645374 abstract "For patients with resectable, early-stage non-small-cell lung cancer (NSCLC), surgery is the primary treatment; however, 5-year survival rates remain poor. Postoperative adjuvant platinum-doublet chemotherapy is associated with a statistically significant but modest improvement in survival of ∼5% at 5 years and is widely accepted as standard of care in patients with resectable, Stage II-III NSCLC. Neoadjuvant chemotherapy has been associated with similar improvements in overall survival to adjuvant therapy in this setting. Durvalumab, a high-affinity PD-L1 inhibitor, has become the standard of care for patients with unresectable, Stage III NSCLC following chemoradiotherapy based on improved progression-free and overall survival in the phase III PACIFIC trial. AEGEAN is a phase III, double-blind, placebo-controlled, international study that will assess pathological and clinical outcomes of durvalumab plus chemotherapy prior to surgery, followed by durvalumab monotherapy after surgery in adults with resectable, Stage II-III NSCLC. Approximately 800 patients will be randomized (1:1) to receive durvalumab or placebo every 3 weeks (q3w) alongside platinum-based chemotherapy (≤4 cycles) prior to surgery, followed by durvalumab or placebo monotherapy q4w, for an additional 12 cycles post surgery, stratified by disease stage (IASLC 8th Edition, Stage II vs. Stage III) and PD-L1 tumor cell expression levels (<1% vs. ≥1%). Primary endpoints include pathological complete response and event-free survival for patients with wild-type EGFR and ALK. Key secondary efficacy endpoints include major pathologic response, disease-free survival and overall survival." @default.
• W3207645374 created "2021-10-25" @default.
• W3207645374 creator A5001948668 @default.
• W3207645374 creator A5046728958 @default.
• W3207645374 creator A5048380048 @default.
• W3207645374 creator A5067283294 @default.
• W3207645374 creator A5072962250 @default.
• W3207645374 creator A5075467295 @default.
• W3207645374 creator A5081110935 @default.
• W3207645374 creator A5091485383 @default.
• W3207645374 date "2022-05-01" @default.
• W3207645374 modified "2023-10-16" @default.
• W3207645374 title "Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial" @default.
• W3207645374 cites W1971740062 @default.
• W3207645374 cites W1988160404 @default.
• W3207645374 cites W1996863944 @default.
• W3207645374 cites W2019204011 @default.
• W3207645374 cites W2024091455 @default.
• W3207645374 cites W2104504726 @default.
• W3207645374 cites W2114238186 @default.
• W3207645374 cites W2134291074 @default.
• W3207645374 cites W2182482244 @default.
• W3207645374 cites W2228221433 @default.
• W3207645374 cites W2743407421 @default.
• W3207645374 cites W2753065806 @default.
• W3207645374 cites W2798160602 @default.
• W3207645374 cites W2893824814 @default.
• W3207645374 cites W2943492451 @default.
• W3207645374 cites W2977392388 @default.
• W3207645374 cites W3003197494 @default.
• W3207645374 cites W3016210953 @default.
• W3207645374 cites W3021010739 @default.
• W3207645374 cites W3087210493 @default.
• W3207645374 cites W3089266118 @default.
• W3207645374 cites W3094192068 @default.
• W3207645374 cites W3125059937 @default.
• W3207645374 cites W3132841322 @default.
• W3207645374 cites W3165887339 @default.
• W3207645374 cites W3172131160 @default.
• W3207645374 cites W3199580546 @default.
• W3207645374 doi "https://doi.org/10.1016/j.cllc.2021.09.010" @default.
• W3207645374 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34819266" @default.
• W3207645374 hasPublicationYear "2022" @default.
• W3207645374 type Work @default.
• W3207645374 sameAs 3207645374 @default.
• W3207645374 citedByCount "26" @default.
• W3207645374 countsByYear W32076453742022 @default.
• W3207645374 countsByYear W32076453742023 @default.
• W3207645374 crossrefType "journal-article" @default.
• W3207645374 hasAuthorship W3207645374A5001948668 @default.
• W3207645374 hasAuthorship W3207645374A5046728958 @default.
• W3207645374 hasAuthorship W3207645374A5048380048 @default.
• W3207645374 hasAuthorship W3207645374A5067283294 @default.
• W3207645374 hasAuthorship W3207645374A5072962250 @default.
• W3207645374 hasAuthorship W3207645374A5075467295 @default.
• W3207645374 hasAuthorship W3207645374A5081110935 @default.
• W3207645374 hasAuthorship W3207645374A5091485383 @default.
• W3207645374 hasBestOaLocation W32076453741 @default.
• W3207645374 hasConcept C121608353 @default.
• W3207645374 hasConcept C126322002 @default.
• W3207645374 hasConcept C141071460 @default.
• W3207645374 hasConcept C142724271 @default.
• W3207645374 hasConcept C143998085 @default.
• W3207645374 hasConcept C146357865 @default.
• W3207645374 hasConcept C151730666 @default.
• W3207645374 hasConcept C203092338 @default.
• W3207645374 hasConcept C204787440 @default.
• W3207645374 hasConcept C27081682 @default.
• W3207645374 hasConcept C2776256026 @default.
• W3207645374 hasConcept C2776694085 @default.
• W3207645374 hasConcept C2777701055 @default.
• W3207645374 hasConcept C2777742743 @default.
• W3207645374 hasConcept C2778424827 @default.
• W3207645374 hasConcept C2780030458 @default.
• W3207645374 hasConcept C535046627 @default.
• W3207645374 hasConcept C71924100 @default.
• W3207645374 hasConcept C86803240 @default.
• W3207645374 hasConceptScore W3207645374C121608353 @default.
• W3207645374 hasConceptScore W3207645374C126322002 @default.
• W3207645374 hasConceptScore W3207645374C141071460 @default.
• W3207645374 hasConceptScore W3207645374C142724271 @default.
• W3207645374 hasConceptScore W3207645374C143998085 @default.
• W3207645374 hasConceptScore W3207645374C146357865 @default.
• W3207645374 hasConceptScore W3207645374C151730666 @default.
• W3207645374 hasConceptScore W3207645374C203092338 @default.
• W3207645374 hasConceptScore W3207645374C204787440 @default.
• W3207645374 hasConceptScore W3207645374C27081682 @default.
• W3207645374 hasConceptScore W3207645374C2776256026 @default.
• W3207645374 hasConceptScore W3207645374C2776694085 @default.
• W3207645374 hasConceptScore W3207645374C2777701055 @default.
• W3207645374 hasConceptScore W3207645374C2777742743 @default.
• W3207645374 hasConceptScore W3207645374C2778424827 @default.
• W3207645374 hasConceptScore W3207645374C2780030458 @default.
• W3207645374 hasConceptScore W3207645374C535046627 @default.
• W3207645374 hasConceptScore W3207645374C71924100 @default.
• W3207645374 hasConceptScore W3207645374C86803240 @default.
• W3207645374 hasFunder F4320307770 @default.
• W3207645374 hasIssue "3" @default.

• next